Yaping Shou

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Hagop M. Kantarjian, Francis J. Giles, Norbert Gattermann et al. · Blood · 2007 · 745 citations · Full text

Medicine, Oncology, Pharmacology +9

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

Hagop M. Kantarjian, Francis J. Giles, Kapil N. Bhalla et al. · Blood · 2010 · 379 citations

Pharmacy, Pharmacology, Pharmacotherapy +5

Diverse karyotypic abnormalities of the c <i>-myc</i> locus associated with c <i>-myc</i> dysregulation and tumor progression in multiple myeloma

Yaping Shou, Marialuisa Martelli, Ana Gabrea et al. · Proceedings of the National Academy of Sciences · 2000 · 349 citations · Full text

Medicine, Cancer Biology, Oncology +17

Impact of Baseline <i>BCR-ABL</i> Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Timothy P. Hughes, Giuseppe Saglio, Susan Branford et al. · Journal of Clinical Oncology · 2009 · 309 citations · Full text

Life Sciences, Oncology, Pharmacotherapy +14

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

Philipp le Coutre, Oliver G. Ottmann, Francis J. Giles et al. · Blood · 2007 · 291 citations · Full text

Medicine, Oncology, Pharmacology +4